Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Fig. 4

Association of ANK2 mutation with immune-related signatures in LUAD. A: Differences in immune cell infiltration between ANK2-MT and ANK2-WT LUAD. B, C: Differences in immuno-stimulators (B) and immuno-inhibitors (C) between ANK2-MT and ANK2-WT LUAD. D: Correlation of ANK2 mutation with the expression levels of MHC molecules in LUAD. E, F: The effect of ANK2 mutation on the expression of chemokines (E) and their receptors (F) in LUAD (*P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us